ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Boehringer Ingelheim at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Boehringer Ingelheim takes part in 1 session at ESMO 2026 in Madrid, and exhibits at Booth 1065. Its program centres on the next generation of targeted cancer therapy aimed at HER2 and DLL3. The topic fits its development of zongertinib for HER2-mutant lung cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned German pharmaceutical company developing oncology drugs such as zongertinib for HER2-mutant lung cancer. | Booth Exhibiting at Booth 1065 Satellite Sat Oct 24 18:30–20:00 |
Find decision makers at Boehringer Ingelheim
Tell us what you sell and we’ll find the people at Boehringer Ingelheim most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction